OncoDaily Grand Rounds: AI in Oncology Edition was convened during ASCO 2026 in Chicago, with ZS serving as the exclusive partner. Held on May 30, 2026, from 5:00 to 8:00 PM at the Hyatt Regency McCormick Place, the evening brought together a diverse group of leaders working across oncology, life sciences, technology, diagnostics, data science, and patient advocacy.
The program created a space for scientific exchange and meaningful professional networking around one of the most important questions facing modern cancer care: how can artificial intelligence be responsibly integrated into research, clinical decision-making, care delivery, and the future of oncology practice?
More than 250 participants attended, including leaders from organizations such as AstraZeneca, Johnson & Johnson, Tempus, PathAI, ConcertAI, AlphaMab, Biocartis, Triomics, Cureety, and the American Oncology Network, alongside experts in precision medicine, digital pathology, real-world data, clinical genomics, health policy, and patient advocacy. Through this multidisciplinary dialogue, the Grand Rounds explored not only the potential of AI to accelerate innovation, but also the need to ensure that its use remains evidence-based, equitable, transparent, and centered on patients.
Chair
| Images | Name |
|---|---|
 | Douglas Flora MD, LSSBB, is board-certified medical oncologist, cancer survivor, and executive leader, he serves as Executive Medical Director of the Yung Family Cancer Center at St. Elizabeth Healthcare and Editor-in-Chief of AI in Precision Oncology. Author of Rebooting Cancer Care and President-Elect of the Association of Cancer Care Centers (ACCC), he is dedicated to advancing prevention, early detection, innovation, and equity across the cancer care continuum. As CEO of TensorBlack and a frequent keynote speaker, he champions the responsible integration of AI and emerging technologies to transform oncology while keeping compassionate, patient-centered care at the forefront. |
Co-Host
| Images | Name |
|---|---|
 | Pavankumar Anné is a Principal in the Boston office of ZS and leads the firm’s Global Oncology and Precision Medicine Practice. With over 15 years at ZS, he has supported oncology companies across medical, marketing, and sales functions, with experience spanning most tumor types and deep expertise in commercialization strategy and organizational design. |
Speakers
| Images | Name |
|---|---|
 | Cristian Massacesi, MD, is Executive Vice President, Chief Medical Officer, and Head of Development at Bristol Myers Squibb, overseeing global early- and late-stage development across oncology/hematology, neuroscience, immunology, and cardiovascular diseases, with more than 100 clinical trials and a team of ~6,000. A trained medical oncologist, he has over 20 years of drug development experience. Prior to joining BMS in August 2025, he served as Chief Medical Officer of AstraZeneca and Alexion, and Oncology Chief Development Officer at AstraZeneca, leading over 150 clinical studies and multiple regulatory approvals. He also held senior R&D roles at Pfizer and Novartis. He earned his MD from Marche Polytechnic University, trained at the Royal Marsden Hospital and other leading institutions, and has authored over 50 peer-reviewed publications. |
 | Debra Patt, MD is a practicing oncologist and breast cancer specialist in Austin, Texas, and Executive Vice President of Texas Oncology, focusing on healthcare policy and strategic initiatives. She also serves as managing partner for the Central Texas, Gulf, and Rio Grande Valley regions since 2023. She is the Medical Director for Public Policy for The US Oncology Network and has testified before the US Congress and Senate to protect cancer care access. Dr. Patt is President of the Community Oncology Alliance, a member of the ASCO Board of Directors, and chairs ASCO’s Artificial Intelligence Task Force. She is also a professor at Dell Medical School at The University of Texas at Austin and is active in advancing digital healthcare tools in oncology. |
 | Sanjay Juneja, MD is a triple board-certified hematologist and medical oncologist and Vice President of AI & Medical Informatics at Tempus AI, where he leads clinical AI strategy in oncology. He is the author of “We Need to Talk About Cancer” and creator of “TheOncDoc,” reaching over 750,000 professionals worldwide. He maintains a clinical practice with Citrus Oncology, completed Harvard’s AI in Healthcare program, and serves on the Editorial Board of AI in Precision Oncology. His honors include Targeted Oncology’s 2024 Oncology Icon, a White House invitation, 40 Under 40, and recognition among the Capital Region’s Top 500 Most Influential Leaders for three consecutive years. Featured in major outlets like The Washington Post and Bloomberg, he is also co-founder of TensorBlack Inc. His AI and healthcare podcast has over 5 million downloads in 110+ countries. |
 | Sunil Verma, MD, is Senior Vice President and Global Head of the Oncology Franchise at AstraZeneca, where he leads global oncology strategy and a late-stage portfolio across multiple tumor types. With more than 25 years of experience spanning clinical practice, academia, and pharmaceutical leadership, he has played a key role in advancing cancer research and innovation. Dr. Verma has contributed to more than 50 major clinical trials and authored over 125 peer-reviewed publications that have helped shape oncology practice. Before joining AstraZeneca, he served as Professor and Academic/Clinical Department Head of Oncology at the University of Calgary, as well as Medical Director of the Tom Baker Cancer Centre. He is also widely recognized for his commitment to education, mentorship, and leadership development in oncology. |
Participants
| Images | Name |
|---|---|
 | Gabriela Beatriz Norese, MD, MSc, is a medical oncologist specializing in breast surgery, gynecologic oncology, medical genetics, and genomics. She serves as Head of the Hereditary Cancers and Precision Medicine Section in the Gynecology Division at Buenos Aires University Hospital, Associate Professor at the Faculty of Medicine of the University of Buenos Aires, and Medical Director of International Argenetics Laboratory in Argentina. Her work focuses on hereditary cancers, precision medicine, cancer genetic counseling, and genomic platforms in breast and gynecologic oncology. She has authored and co-authored several recent publications and book chapters on hereditary breast cancer, genetic risk assessment, genitourinary cancer genetics, and the role of artificial intelligence in oncology. |
 | Regina Schwind, MS, MBA, is a senior life sciences executive and translational oncology researcher with more than 20 years of experience across academic medicine, biotechnology, real-world data, and AI. She serves as Chief Data Officer at Triomics, where she leads clinical-genomic data strategy, research informatics, AI initiatives, and real-world data commercialization. Previously, she was Senior Director of Real-World Data and Head of Clinical Data at Tempus AI, where she helped launch and scale the company’s data licensing business and led a team of more than 350 professionals. Her career also includes leadership roles at The Ohio State University Comprehensive Cancer Center and UI Health, where she contributed to the launch of the UI Cancer Center and the development of the Oncopig Cancer Model™. Her work has supported over $5M in federal research funding, high-impact publications, and the translation of scientific innovations into clinical and commercial impact. |
 | Dr. Lindsey Cotton is a clinician-researcher, implementation scientist, and nationally recognized speaker working at the forefront of AI-enabled cancer care. Her work focuses on clinical care, precision medicine, emerging diagnostics, biomarkers, and real-world evidence, with an emphasis on turning innovation into scalable oncology solutions that improve access and clinical impact. She has led national trials and implementation initiatives in lung cancer screening and diagnostic innovation, including programs highlighted by the Biden Cancer Moonshot for expanding early cancer detection in underserved communities. Her work has helped advance blood-based lung cancer screening across major health systems, including tribal and Indigenous care settings. Dr. Cotton is also an author, faculty member, scientific reviewer, and moderator for major oncology and pulmonary conferences, including CHEST, and contributes to international lung cancer guideline efforts addressing stigma, bias, and clinical language standards. |
 | Adiba Zeito is the Founder and President of AICANcer Patient Advocacy Group, a patient-led non-profit dedicated to ensuring that AI in oncology is developed with equality, integrity, empathy, and a patient-centered focus. A long-time tech and startup leader with experience across Stockholm and Silicon Valley, she previously led Innovative Sweden and became the youngest CEO in Silicon Valley Forum’s 30-year history. After being diagnosed with breast cancer at 27 and later metastatic breast cancer, Adiba became a powerful advocate for people living with cancer, serving with organizations including Susan G. Komen, METAvivor, the MBC Alliance, and the Swedish Breast Cancer Foundation. She founded AICANcer at the intersection of her lived experience as a cancer patient and her deep background in technology, bringing a unique voice to the future of AI-driven cancer care. |
 | Karan Cushman is a patient advocate and strategic communications leader focused on precision oncology and emerging technologies in cancer care. She works across research, clinical, and technology communities to support adoption, education, and equitable access in oncology, with a particular focus on rural healthcare. Karan is Founder of Cushman Creative and Co-founder and Host of the award-winning Precision Medicine Podcast, a global platform exploring the real-world impact of innovation in oncology. |
 | Erin Fidyk, MSN, MBA, is Director, Oncology Enterprise Data, Data Science & AI at Johnson & Johnson Innovative Medicine. A clinician by training, she works at the intersection of oncology, artificial intelligence, and diverse health data domains, with a focus on translating emerging technologies into meaningful impact across research and development |
 | Emre Baser, MD is a physician with international medical training and serves as Director of Medical Diagnostics at AstraZeneca. He leads initiatives across precision medicine, oncology, molecular pathology, and diagnostics, bringing strong clinical insight to the advancement of precision oncology. He has led collaborative research and education projects across the healthcare ecosystem, with a focus on patient-centered innovation, diagnostic excellence, and improving outcomes through knowledge and collaboration |
 | Ting Xu is the CEO and President of AlphaMab, a China-based biotechnology company focused on innovative therapies in immuno-oncology, antibody-drug conjugates, and complex biologics. Under his leadership, AlphaMab has advanced multiple products into Phase III clinical trials and strengthened its position in the development of bispecific antibodies and ADCs. He also guided the company through its 2019 listing on the Hong Kong Stock Exchange, a key milestone in AlphaMab’s growth and presence in the global biotech landscape. |
 | Ashley Easter is Head of the Global QCS Team at AstraZeneca, leading cross‑functional efforts to deploy the organisation’s novel QCS computational pathology technology into AstraZeneca’s late‑development oncology pipeline. AstraZeneca believes that AI‑enabled computational pathology will underpin the development of the next generation of cancer therapies and diagnostics. Previously, Ashley was Head of Strategy and Partnerships for the Global Diagnostics team and has held several other diagnostic‑adjacent roles across R&D and commercial functions at AstraZeneca. Before joining AstraZeneca, Ashley worked as a scientific consultant and holds a PhD in Molecular Biology from Cambridge. |
 | Beyza Klein is a Global Patient Advocacy Director in Oncology R&D at Johnson & Johnson, where she leads insight-driven strategies that embed the patient voice across the clinical development lifecycle. Her work focuses on improving trial planning, recruitment, retention, and outcomes through patient insights, real-world evidence, and collaboration with patient organizations worldwide. Trained as a sociologist with postgraduate studies from the University of Sydney, Beyza brings expertise in qualitative and quantitative research to advance patient-centered innovation and equitable access to meaningful cancer therapies. |
 | Sebastien Rhodes - Chief Business Officer at Triomics: Sebastien leads the strategy, commercial, and operations functions at Triomics. He focuses on identifying and validating strategic use cases for their OncoLLM platform across the provider and life science value chains and bridging the gap between AI / product and Triomics' key strategic collaborators to safely implement and deploy these solutions at scale. Previously, Sebastien was a chief of staff, strategist, and leading venture investor focused on advancements in digital health and health technology.
|
 | Andrea Anampa-Guzmán, MD, is an oncology physician-scientist specializing in clinical pharmacology and translational medicine. She is currently a Clinical Pharmacology Fellow at the Mayo Clinic and an FDA–American Association for Cancer Research Oncology Educational Fellow. Her work focuses on leveraging pharmacokinetic/
|
 | Seong Chi, MD, is a strategic patient advocacy leader with over 10 years of experience in biotech and pharmaceutical oncology. Currently serving as Associate Medical Director of Scientific Advocacy at AbbVie Oncology, he has built patient advocacy functions from the ground up, launched multiple therapies, and forged partnerships with leading organizations including the International Myeloma Foundation and Blood Cancer United. A former AstraZeneca and Labcorp Oncology marketing and training leader, he brings deep expertise in KOL engagement, clinical trial enrollment, and health equity. Dr. Chi holds an MD from Windsor University School of Medicine and a BA from Boston College. |
 | Misha Kaur is the Chief Operating Officer of Cureety, an oncology-focused digital health company advancing patient-centered cancer care beyond hospital walls. She leads global strategy and operations for platforms that support proactive remote patient monitoring, AI-enabled triage, coordinated clinical workflows, and value-based oncology care. With nearly two decades of experience across healthcare, public policy, and system transformation, Misha previously served as a Senior Advisor at the OECD and spent 15 years in the Australian Government, including as Assistant Commissioner. Her work focuses on translating complex health-system challenges into scalable solutions that improve outcomes for patients, care teams, and health systems. |
 | Matthew Lee, M.D., MPH, is an assistant professor of medical oncology at City of Hope® Cancer Center Duarte, specializing in diagnosing and treating patients with lung cancer, including small cell lung cancer. His research focuses on targeted therapies, antibody-drug conjugates, cellular therapies, immunotherapy, and liquid biopsies (ctDNA) for risk stratification and diagnosis along with the use of AI and incorporating a multimodal approach to diagnosis and treatment utilizing radiomics and digital pathology. He is also actively involved in ECOG-ACRIN, ETCTN, Hoosier Cancer Research Network, and the Small Cell Lung Cancer Consortium. An active researcher, Dr. Lee has published over a dozen peer-reviewed articles, contributed to multiple clinical trials, and have been recognized with awards from the International Association for the Study of Lung Cancer.
|
 | Mark Moch is a healthcare technology executive and AI strategist advancing data-driven innovation in community oncology. He serves as Chief Information Officer at the American Oncology Network (AON), where he has helped build the technology infrastructure supporting the network’s growth across more than 300 providers in 20 states. He is also Managing Partner of MiBA, an AI-powered oncology intelligence platform that transforms real-world clinical data into actionable insights for physicians, life sciences companies, payers, and research organizations. His work leverages natural language processing, large language models, and machine learning to support clinical trial matching, drug development, treatment decisions, and precision oncology. A recipient of the 2023 CIO of the Year ORBIE Award, Mark is committed to using AI to help deliver the right treatment to the right patient at the right time. |
 | Jeff Elton, Ph.D., is Vice Chairman of ConcertAI, a multi-modal data and AI SaaS company advancing patient-centered research and clinical solutions for life sciences innovators, research sites, and healthcare providers. His work focuses on improving the speed and precision of clinical studies through real-world data drawn from electronic medical records, laboratory systems, and imaging platforms. ConcertAI supports more than 1,900 healthcare providers, over 200 research sites, and collaborates with organizations including ASCO through the CancerLinQ initiative. Previously, Jeff held senior leadership roles at Accenture, Novartis Institutes for BioMedical Research, and McKinsey & Company. He is also Vice Chair of the Massachusetts Biotechnology Council, a board member and advisor to early-stage companies, and co-author of Healthcare Disrupted. |
 | Andrea Wilson Woods is a keynote speaker, a writer who loves to tell stories, and a patient advocate who founded the nonprofit Blue Faery: The Adrienne Wilson Liver Cancer Association. For over 10 years, Andrea worked in education as a teacher and professor in public and private schools and universities. Andrea obtained her master’s degree in professional writing from the University of Southern California; her nonfiction writing has won national awards. Her best-selling and award-winning book, Better Off Bald: A Life in 147 Days, is a medical memoir about raising and losing her sister to liver cancer.
|
 | Greg Gillum is Director of Medical Impact & Data Enablement at Boehringer Ingelheim, bringing over 20 years of experience across specialty sales and medical affairs. A recognized subject matter expert in AI in Medical Affairs, Greg leads high-profile projects leveraging analytics and artificial intelligence to transform ways of working. His expertise spans medical affairs, field-based medicine, MSL engagement, oncology and virology, with a focus on driving data-driven insights that enhance scientific impact and improve patient outcomes. |
 | Dr. Ira Klein is Vice President of Medical Affairs for Payor Relations at Tempus, where he leads work across payer policy, payment and revenue cycle management, market access, and AI-enabled healthcare solutions. With extensive experience in payer strategy, oncology, and healthcare operations, he previously served as Chief Medical Officer of Health New England, led Healthcare Quality Strategy across Janssen’s therapeutic areas, and held multiple national medical leadership roles at Aetna, including founding its Oncology Solutions team. Dr. Klein is widely published in leading oncology and managed-care journals and brings expertise in health information technology, artificial intelligence, pharmacoeconomics, and value-based care. |
 | Alyssa Hill is a Senior Medical Science Liaison at Daiichi Sankyo for the breast team in the South West district. She has been a part of the breast MSL team at DSI for 5 years.Prior to joining Daiichi Sankyo, Alyssa spent 10 years at Banner MD Anderson Cancer Center most recently as the clinical research pharmacy lead. Alyssa graduated from University of AZ College of Pharmacy with her Pharm D. She resides in Gilbert, AZ with her husband and two sons. |
 | Victoria L Chiou, MD, is Vice President, Clinical Development at Tempus AI. Dr Chiou is an oncology research physician with academic, industry, and regulatory experience in patient-centric drug development. Prior diverse clinical development experiences include Head, Clinical Excellence and Innovation, Late Development Oncology at AstraZeneca, where she led strategic development and implementation of global initiatives at the intersection of clinical cancer research, technology, and innovation; GlaxoSmithKline in cell therapy; and MedImmune/AstraZeneca in novel immuno-oncology drug combinations for treatment of multiple cancers. Dr Chiou also served as a medical officer at the US Food and Drug Administration, Office of Hematology and Oncology products. Dr Chiou completed her BA in human biology and psychology as a Jefferson Scholar at University of Virginia, MD at Medical College of Virginia, internal medicine residency at Wake Forest University, and medical oncology fellowship at National Institutes of Health, National Cancer Institute. Multiple career recognitions include Conquer Cancer Foundation of ASCO Merit Award, ASCO/AACR Methods in Clinical Cancer Research Workshop, SITC Women in Cancer Immunotherapy Network Leadership Institute, and Maryland Leading Women Under 40.
|
 | Edward Esplin, MD, PhD, is a physician-scientist and clinical geneticist specializing in precision medicine, germline and tumor genomic testing, and genomic screening. He serves as Senior Vice President of Medical Affairs at Biocartis and previously spent more than a decade at Invitae, where he helped advance clinical research, regulatory strategy, and access to genomic testing, including the first FDA de novo authorization for the Invitae Common Hereditary Cancers panel. His work has included major studies in pan-cancer screening, prostate cancer, universal germline testing, and population genomic screening, and he has co-authored more than 100 scientific publications. Dr. Esplin trained at UT Southwestern and Stanford University and remains involved in academic research through the Stanford Pre-Cancer Atlas and the NIH Human Tumor Atlas Network. |
 | Rebecca Wray is Head of Strategy for Late Development Oncology at AstraZeneca, where she leads global portfolio strategy across major solid tumors and helps shape how late-stage assets are prioritized, developed, and brought to patients. She has also helped advance AstraZeneca’s digital health strategy in oncology, with a focus on the practical use of artificial intelligence across clinical development, trial design, patient identification, remote monitoring, and real-world data. Rebecca works closely with the healthcare start-up ecosystem to bring emerging technologies into oncology development and contributes to early-stage innovation through the Royal Academy of Engineering. She holds an MEng in Engineering and is completing executive studies at the University of Oxford. |
 | Eric E. Walk, MD, FCAP, is Chief Medical Officer at PathAI, where he leads Medical Affairs, Pathology, Clinical Science, Regulatory, and Quality functions. With more than 20 years of experience in precision medicine, oncology drug development, companion diagnostics, and AI pathology, he has helped advance biomarker-driven strategies and digital pathology innovation across the industry. Before joining PathAI, Dr. Walk served as Chief Medical and Scientific Officer at Roche Tissue Diagnostics/Ventana Medical Systems, leading the validation and regulatory advancement of in vitro diagnostic assays, companion diagnostics, and digital pathology algorithms. Earlier, he held roles in early clinical development and translational medicine at Novartis Oncology. A board-certified anatomic and clinical pathologist, Dr. Walk is active in leading pathology and immuno-oncology organizations and has published on generative AI, digital pathology, and tumor immune biology. |
 | Esranur Aydın is a Clinical Cancer Scientist at Medicana Health Group, specializing in precision oncology and individualized cancer treatment planning. Her work focuses on integrating comprehensive genomic profiling into clinical decision-making and translating molecular findings into personalized therapeutic strategies. She contributes to multidisciplinary tumor boards, helping develop patient-specific treatment plans based on each tumor’s molecular profile. With a background in molecular oncology and genetics, Esranur is particularly interested in optimizing targeted therapies, combination approaches, and the use of emerging biomarkers to advance precision-driven cancer care. |
 | Enrique García Olazábal, MD, MSc, is an oncology and medical affairs professional serving as Oncology Medical Lead for Latin America. With training in clinical oncology and molecular biology, he brings an evidence-based, patient-centered perspective to the development and implementation of medical strategies across the region. His work focuses on improving patient outcomes, supporting the launch of innovative treatments, and building meaningful collaborations with key opinion leaders and multidisciplinary healthcare teams. Based in Montevideo, Uruguay, Dr. García Olazábal combines clinical insight, scientific expertise, and a strong commitment to continuous professional development to address complex challenges in oncology care. |
Read the full post-event summary here
ZS as Exclusive Partner
ZS served as the exclusive partner for the AI in Oncology Edition. Founded in 1983, ZS is a management consulting and technology firm with more than 13,000 employees across over 35 offices worldwide. The company works with organizations across data, science, technology, and strategy to support better outcomes across healthcare and other sectors.
Its involvement in the program reflected the increasing importance of cross-sector collaboration as oncology moves toward more data-driven, technology-enabled models of care and research.